Connect with us


The Biogenera and Spac Life Care Capital collaboration

The shareholders and founders of “Biogenera”, a medium-sized biotech company, signed an agreement with “Life Care Capital”. Biogenera is a company that has created an internationally patented method to generate a new era of personalized DNA drugs for incurable diseases. Life Care Capital will buy shares of Biogenera at a unit price of $37.3 (€34.4) per share.



This picture shows a newspaper with some data.

Spac Life Care Capital has chosen a target for their business combination. Specifically Biogenera, a company specialized in the research and development of biotechnological drugs on a genetic basis for the treatment of serious diseases both in children and adults.

In detail, Meta Ventures, the shareholders of Italian Angels for Growth (IAG), the Emilia-Romagna Region, and the founders, Andrea Pession and Roberto Tonelli, representing about 85% of Biogenera’s share capital, have signed a framework agreement with Life Care Capital that will lead to the merger of LCC into Biogenera. Equita sim acts as Nomad and Life Care Capital Specialist. Biogenera has been assisted by Alantra as a financial advisor.

LCC, the only Italian thematic Spac in the health&life care sector, was promoted by Carlo Castellano, Alessandra Gavirati, Luigi Sala, Jody Vender, and Techwald and listed at Aim Italia in March 2018 after raising $152 million (€140 million) from investors.

Business news, financial headlines, news about Africa, biotech industry, crowdfunding, and much more, you can find with the Born2Invest mobile app.

The biotech company Biogenera

Biogenera is an innovative medium-sized biotech company founded in 2008, following a patent by created by the two founders: Andrea Pession (Professor of Paediatrics at the University of Bologna, U.O. Director of Pediatrics Ospedale Sant’Orsola in Bologna and Director of the Interdepartmental Centre for Cancer Research “Giorgio Prodi”) and Roberto Tonelli, researcher in Pharmacology at the University of Bologna.

The company has created a unique and internationally patented method of generating a new era of personalized DNA drugs for incurable diseases. In particular, the company has developed MyGenera, a platform used to identify potential drug candidates for potential therapeutic targets on which it is not possible to use already available drug technologies. Biogenera has already completed pre-clinical studies of its first BGA001 drug for the treatment of tumors in children and in a few months, it is expected to start phase 1 clinical trials, particularly in neuroblastoma.

The company was supported with a first-round seed by Meta Ventures, IAG members and the Emilia-Romagna Region. In addition, it resorted twice to equity crowdfunding: first in 2017 through the 200Crowd platform, when it had raised $412.940 (€381.000), and then in 2018 with BackToWork. Thanks to this last campaign, the company has collected over $774.930 (€715.000), recording an overfunding of 615% on the minimum target of $108.380 (€100.000). At that time the company was assigned a pre-money value of $7.9 million (€7.32 million).

Life Care Capital will purchase Biogenera shares

The Framework Agreement provides that Life Care Capital will purchase Biogenera shares in a number equal to 5% of the capital from Andrea Pession and Roberto Tonelli and that Meta Ventures will acquire shares equal to 22.5% of the capital. In total there are approximately 471 thousand Biogenera shares equal to 32.5% of the capital.

In addition, Life Care Capital is committed to purchasing all the Biogenera shares from Biogenera’s shareholders (other than Andrea Pession, Roberto Tonelli and Meta Ventures) who exercise the right of co-sale under the terms of the articles of association.

The business combination will be completed through the purchase by LCC of the Biogenera shares of the two founders and Meta Ventures for $17.5 million (€16.2 million), at a unit price of $37.3 (€34.4) per share. For the purposes of the merger, an equity value of $76 million (€70 million) has been attributed to Biogenera and an equity value of approximately $151 million (€139 million) to LCC.

At the time of the business combination, the free float percentage represented by the current investors in Life Care Capital will be between approximately 66.1% of the share capital (in case of withdrawal up to 30% of Life Care Capital) and approximately 68.5% of the share capital (in case of withdrawal equal to zero). The Life Care Capital shareholders’ meeting, which will be called to approve the business combination, will also be called to approve a distribution of an extraordinary dividend in favor of its shareholders who have not exercised their right of withdrawal for a maximum of $33 million (€30 million).

A value of production reached $421.590

In view of the fact that Biogenera’s business has so far consisted exclusively of research and development, on December 31st, 2019 it reported a value of production of $421.590 (€389.000) and a loss of $445.350 (€410.000).

The first Board of Directors of the post-merger company will be made up of six directors appointed by LCC, including Alessandra Gavirati (as Chairman), Luigi Colombo (as Chief Operating Officer) and Alessandro Piga; two directors appointed by the founding partners, namely Andrea Pession (as Vice Chairman, Chief Medical Officer, and Chief Scientific Officer) and Stefano Biondi; one independent director. The founding partners have undertaken a lock-up commitment for a period of 36 months; the same commitment was undertaken by Meta Ventures for a period of 24 months.

The shareholders’ meetings of Life Care Capital and Biogenera that will be called to approve the merger and business combination will be held between April and May 2020. The merger deed could be signed by the end of July 2020. Provided it is approved by the LCC shareholders’ meeting and its shareholders do not exercise the right of withdrawal for shares equal to or greater than 30% of LCC’s shares.


(Featured image by Markus Spiske via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in BeBeez, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Daphne Freeman has worked in the crowdfunding and impact investing industry for the past few years, gaining experience in marketing, and connecting businesses and entrepreneurs in need with the right investors. As a seasoned grant writer as well as financial market journalist, she is passionate about making a social impact in the world. A free spirit, Daphne also enjoys writing and exploring topics of interest, currently CBD, health and beauty, and social media influencers.